NORTH CHICAGO (dpa-AFX) - Abbott (ABT) said its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy - as short as 28 days for patients with high bleeding risk. The company noted that XIENCE is the only stent to have evidence and data for both one-month and three-months dual anti-platelet therapy followed by two different types of blood-thinning medication in HBR patients.
'In patients with high bleeding risk, the XIENCE stent has proven that it can ensure patient safety without compromising efficacy when duration of blood-thinning medications is shortened,' said Nick West, chief medical officer and divisional vice president of global medical affairs at Abbott's vascular business.
Copyright RTT News/dpa-AFX